Biology and Treatment of Waldenstrom's Macroglobulinemia

January 30, 2021: Webinar organized by MHG (Mumbai Hematology Group) Supported by ALKEM






Long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib

June 24, 2019: During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Steven Treon from Dana-Farber Cancer Institute, Boston, US, about the long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib.



Genomica E Nuovi Farmaci Cocktail Vincente

Aumenta Fino A 18 Anni La Sopravvivenza Nei Malati Di Waldenstrom
Interview with Dr. Steven Treon in Milan Italy, April 21, 2018 on new research and treatments for Waldenstrom's Macroglobulinemia.




Steven P. Treon, MD, PhD, on Treating Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia

ASCO Post Newsreel: 2016 Pan Pacific Lymphoma Conference
July 18-22, 2016 Koloa, Hawaii
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.




IWMF Videos

2019 WM Foundation Canada (WMFC) Seminar with Patients

WM Foundation Canada (WMFC)
Jewish General Hospital
Montreal, QC, Canada
November 7, 2019
Steven P. Treon MD, PhD, FACP, FRCP – Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute
In this video, Dr. Steven P. Treon speaks to a Montreal patient group providing updates on the genomics and latest treatment options for Waldenstrom’s macroglobulinemia.



Breaking News from the WM Front (2019 Ed Forum)

Explains why CR is so uncommon in WM, even with targeted therapy, what are the WM-centric toxicities with commonly used therapies, how pro-survival signaling of WM cells is driven by mutated MYD88 in WM, how CXCR4 mutations permit ongoing pro-survival signaling of Wm cells by CXCL12 and makes CXCR4 resistant to ibrutinib and the impact of CXCR4 on WM response and progression free survival (PFS). Reviews studies with ibrutinib, venetoclax, a combination of both drugs, zanubrutinib, acalabrutinib, and incorporating other novel treatments to eradicate residual or resistant disease. Also explains what the knowledge gaps are for developing more effective treatments for patients with WM without MYD88 mutations. Bing Neel Syndrome, and WM-related P/N also.


Ask the Doctor Panel 2019

Moderated by Tom Hoffmann, MD – IWMF Trustee, 2019 Ed Forum
Researchers and clinicians answer, and sometimes debate, questions from the audience






Genomic & Treatment Advances in Waldenstrom's Macroglobulinemia

Zachary Hunter, PhD, Guang Yang, PhD, Steve Treon, MD, PhD – Dana Farber Cancer Institute, 2018 Ed Forum
Three researchers discuss how MYD88 and CXCR4 mutations are common in WM with MYD88 activating BTK and HCK in WM cells, both targets of ibrutinib. Ibrutinib produces high response rates and durable responses in relapsed and refractory WM. No complete responses. Mutated CXCR4, aberrant IRAK and BCL2 signaling contribute to intrinsic resistance against ibrutinib. Multiple BTK mutations are common with acquired ibrutinib resistance and trigger ERK1/2 survival signaling. Novel strategies to overcome intrinsic and acquired resistance to ibrutinib, including targeting CXCR4, ERK, IRAK, and BCL2 signaling.


New Insights into the Biology & Therapy of WM

Steven Treon, MD, PhD – Dana-Farber Cancer Institute, 2017 Ed Forum
Discusses manifestations of WM, side effects, genomics, treatment options, upfront treatment and relapsed/refractory treatment approaches





Translating Genomic Findings into New Treatment Opportunities for WM

Steven Treon, MD, PhD – Dana-Farber Cancer Institute, 2016 Ed Forum
Reviews WM-centric toxicities with commonly used therapies and discusses new directions in WM based on the MYD88 L265P somatic mutation in WM





IWMF Funding of Landmark Discoveries in WM and how Continued Funding is Critical for Future Management of the Disease

Steven P. Treon, MD, PhD – Dana Farber Cancer Institute, Boston, 2015 Ed Forum
Dr. Treon discusses his interest in WM and WM research, focusing on the whole genome sequencing research supported by the IWMF that helped make the critical discoveries of the MYD88 and CXCR4 mutations. He also mentions that continued funding of WM research is critical to future success in managing the disease.



Targeted Therapies for WM

Steven Treon, MD, PhD – Dana Farber Cancer Institute, 2015 Ed Forum
Explains the WM-centric toxicities with commonly used therapies and new treatment directions in WM, including MYD88 L265P mutation and the MYD88 L265P signal pathway, Ibrutinib studies and its effect on side effects and survival, WHIM-like CXCR4 C-tail mutations in WM, unmutated MYD88 disease in WM, Idelalisib, clinical trial of ABT-199 (BCL2 inhibitor) in relapsed/refractory WM, resistance to Ibrutinib, and Ixazomib clinical trial.



Advances in the Management of WM Revealed by Whole Genome Sequencing (Genomic Based Treatment Advances in WM)

Steven Treon, MD, PhD – Dana Farber Cancer Institute, 2014 Ed Forum
Discusses the NCCN options for treatment of WM, WM-centric toxicities with commonly used therapies, MYD88 L265P in WM /IgM MGUS, MYD88 L265P Signal Pathway and Ibrutinib (inhibitor of BTK), and Idelalisib (inhibitor of P13K-delta).




OncLive Videos

Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia

July 14, 2020: Dr. Treon discusses the role of BTK inhibitors in WM. The advent of BTK inhibitors has led to tremendous progress in the treatment of patients with WM.. BTK inhibitors were developed as a result of identifying MYD88 mutations, which are present in more than 95% of patients with WM.. MYD88 activates BTK through the hematopoietic cell kinase protein. BTK inhibitors include ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa). Additionally, Japanese studies have shown that a fourth BTK inhibitor, tirabrutinib (Velexbru), has shown activity in this patient population. Moreover, the agents have all demonstrated high overall response rates in the 90% range in patients with treatment-naïve, relapsed/refractory, or heavily pretreated WM, concludes Treon.



VJHemOnc Videos

EHA 2019 | Waldenstrom's: Predicting ibrutinib responses

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses data presented at EHA 2019 that investigated predictive factors for long-term response in waldenström’s macroglobulinemia treated with ibrutinib at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.





EMN 2018 | WGS: advancing Waldenström’s diagnosis, prognosis & treatment

The discovery of mutational events in cancer are crucial to the development of efficacious targeted therapies. Here, Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, passionately discusses the genomic advances in Waldenström’s macroglobulinemia (WM), owing to the discovery of the MYD88 and CXCR4 mutations. Dr Treon highlights how these mutations have enabled better understanding of the different forms and metastatic progression of WM, aiding the development of targeted therapies that are revolutionizing the meaning of progression-free survival. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.



ESH MM 2018 | Whole genome sequencing opens door for targeted Waldenström’s therapy

Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenström’s macroglobulinemia (WM), from “hand-me-down” to targeted approaches. The discovery of key growth and survival mutations, such as MYD88, has allowed the development of BTK inhibitors at the core of WM treatment. This video was recorded at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.



ICML 2017 | Exciting times for Waldenström’s macroglobulinemia: new treatments and tools

Steven Treon, MD, PhD, from Dana-Farber Cancer Institute, USA, provides us with a run down of the significant progress made in the understanding of Waldenström’s macroglobulinemia disease pathogenesis and the development of treatments targeted to the condition.



Oncology Learning Network Videos

New Approaches to Treating Waldenström Macroglobulinemia

At the 2019 Lymphoma & Myeloma Congress, Steven Treon, MD, PhD, FACP, FRCP, Harvard University, Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, Massachusetts, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.




BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

June 3, 2020: In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.




Promotional Videos

The 5th International Patient & Physician Summit on Waldenstrom's Macroglubulinemia

This Summit meeting was held on October 13-14, 2018 in New York, as part of the IWWM-10 Workshop on WM. This promotional video offers highlights of the previous four Summit meetings, and welcomes attendees to this meeting in New York.





17th International Workshop on Multiple Myeloma

This promotional video provides an overview of Boston's rich history, internationally renowned educational institutions, world-class science & biotechnology, championship professional sports, diverse dining & cultural attractions, and beautiful scenery. We are proud to be hosting IMW-17 in Boston, a world-class city!





History of the IWWM - Part 1

Highlights of the International Workshops on Waldenstrom's Macroglobulinemia from 2000-2008.

IWWM-1: Washington, DC, USA, September, 2000
IWWM-2: Athens, Greece, September, 2002
IWWM-3: Paris, France, October, 2004
IWWM-4: Kos Island, Greece, June, 2007
IWWM-5: Stockholm, Sweden, October, 2008




History of the IWWM - Part 2

Highlights of the International Workshops on Waldenstrom's Macroglobulinemia from 2010-2018.

IWWM-6: Venice, Italy, October, 2010
IWWM-7: Newport, Rhode Island, USA, August, 2012
IWWM-8: London, UK, August, 2014
IWWM-9: Amsterdam, The Netherlands, October, 2016
IWWM-10: New York, NY, USA, October 2018



The Bing Center

Bing Center for Waldenstrom's

Dana-Farber Cancer Institute

Harvard Medical School

Administrative Contact

Christopher Patterson

Tel: (617)632-6285



Mailing Address

Dana-Farber Cancer Institute

450 Brookline Avenue


Boston, MA 02215